Compare, Analyse ALEMBIC PHARMA with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ALEMBIC PHARMA   ACTAVIS
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
ACTAVIS
Dec-18
ALEMBIC PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs66413,746-   
Low Rs4129,221-   
Sales per share (Unadj.) Rs208.73,371.9-  
Earnings per share (Unadj.) Rs31.0-1,086.1-  
Cash flow per share (Unadj.) Rs37.1355.3-  
Dividends per share (Unadj.) Rs5.500-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs144.213,907.7-  
Shares outstanding (eoy) m188.52332.60-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.63.4 75.7%   
Avg P/E ratio x17.4-10.6 -164.2%  
P/CF ratio (eoy) x14.532.3 44.9%  
Price / Book Value ratio x3.70.8 452.0%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m101,4613,819,451 2.7%   
No. of employees `000NA16.9 0.0%   
Total wages/salary Rs m7,4670-   
Avg. sales/employee Rs ThNM66,361.4-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM-21,375.1-  
INCOME DATA
Net Sales Rs m39,3471,121,508 3.5%  
Other income Rs m9421,447 0.4%   
Total revenues Rs m39,4411,142,955 3.5%   
Gross profit Rs m8,73629,389 29.7%  
Depreciation Rs m1,152479,421 0.2%   
Interest Rs m18464,717 0.3%   
Profit before tax Rs m7,493-493,302 -1.5%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m0125,812 0.0%   
Tax Rs m1,568-6,252 -25.1%   
Profit after tax Rs m5,844-361,238 -1.6%  
Gross profit margin %22.22.6 847.2%  
Effective tax rate %20.91.3 1,650.7%   
Net profit margin %14.9-32.2 -46.1%  
BALANCE SHEET DATA
Current assets Rs m19,577459,984 4.3%   
Current liabilities Rs m14,896406,917 3.7%   
Net working cap to sales %11.94.7 251.4%  
Current ratio x1.31.1 116.3%  
Inventory Days Days9020 458.2%  
Debtors Days Days4566 68.4%  
Net fixed assets Rs m27,097126,948 21.3%   
Share capital Rs m3770-   
"Free" reserves Rs m26,8110-   
Net worth Rs m27,1884,625,699 0.6%   
Long term debt Rs m4,9931,628,876 0.3%   
Total assets Rs m47,7787,231,020 0.7%  
Interest coverage x41.7-6.6 -629.7%   
Debt to equity ratio x0.20.4 52.2%  
Sales to assets ratio x0.80.2 531.0%   
Return on assets %12.6-4.1 -307.7%  
Return on equity %21.5-7.8 -275.2%  
Return on capital %23.6-4.8 -487.6%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m13,3880-   
CASH FLOW
From Operations Rs m8,120400,673 2.0%  
From Investments Rs m-7,556220,117 -3.4%  
From Financial Activity Rs m590-687,674 -0.1%  
Net Cashflow Rs m1,153-66,550 -1.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 71.04 Rs / USD

Compare ALEMBIC PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare ALEMBIC PHARMA With: VENUS REMEDIES  PLETHICO PHARMA  PIRAMAL ENTERPRISES  SUN PHARMA  DR. DATSONS LABS  



Today's Market

Key Q2FY20 Results, Global Stock Market Drivers, and Top Stocks in Action Today(Pre-Open)

On Monday, Indian share markets traded on a positive note most of the day and ended marginally higher. The BSE Sensex closed higher by 87 points to end the day at 38,214.

Related Views On News

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound (Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound? (The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks (Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market (The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound (The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Oct 14, 2019 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - DIVIS LABORATORIES COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS